HUTCHMED Wins Concurrent Approvals for SYVIK After 66% Sustained Response
Key Facts
HUTCHMED announced on November 19, 2026, that China’s National Medical Products Administration granted concurrent approvals for SYVIK, the generic name of which is sovleplenib, to treat two immune disorders in adults. The first approval covers chronic primary immune thrombocytopenia, and the second covers warm antibody autoimmune hemolytic anemia. The company said the approvals were based on results from two separate clinical trials, one Phase III and the other combining Phases II and III. The decision marks the drug’s entry into commercial marketing, according to the company’s filing with the U.S. Securities and Exchange Commission. HUTCHMED described it as the first internally discovered immunology drug to receive commercial approval for the company, expanding its portfolio into immunology beyond oncology.
For immune thrombocytopenia, the approval covers adults with the chronic primary form of the disease who have not achieved an adequate response to at least one prior treatment. The approval was based on ESLIM-01, a randomized, double-blind, placebo-controlled Phase III study in China involving 188 adults who had previously received at least one standard line of treatment. The sustained platelet response rate was 48.4% among patients who received SYVIK, compared with 0% in the placebo group. The company said the comparison recorded a p-value of p<0.0001. This result measured the persistence of platelet response, alongside overall response rates assessed by the study over two time periods.
The overall response rate in ESLIM-01 with SYVIK was 68.3% during weeks 0–12, rising to 70.6% during weeks 0–24. In the placebo group, the rates were 14.5% and 16.1%, respectively, with a p-value of p<0.0001 for the comparison between the groups. These figures show treatment outcomes across two different time windows, while the 48.4% rate separately measures sustained platelet response. The patients covered by this approval are those who did not respond adequately to at least one prior treatment. The immune thrombocytopenia approval therefore covers chronic primary disease in adults who required prior treatment before entering the study.
The approval for warm antibody autoimmune hemolytic anemia, or wAIHA, covers adults who did not respond adequately to prior corticosteroid treatment. It was based on ESLIM-02, a trial combining Phases II and III. During weeks 5–24, the sustained response rate was 66% with SYVIK, compared with 15% in the placebo group, according to the company’s filing. HUTCHMED reported a p-value of p<0.0001 for the comparison. This rate refers to sustained response in the wAIHA trial and does not represent the overall response rate over 24 weeks. The company also described the safety profile in the SYVIK group as favorable and said it recorded no treatment-related deaths or treatment-related discontinuations in that group.
HUTCHMED said the drug is the first immunology medicine discovered in-house by the company to receive approval for commercial marketing, adding a therapeutic area beyond oncology to its business. The company retains full global rights to sovleplenib, according to the filing, and continues to evaluate strategic options to support its global development. This framework leaves development of the drug outside China among the options the company is considering, without changing the scope of the two approvals it announced in the Chinese market. The U.S. Food and Drug Administration granted the drug orphan drug designation in October 2026 for the treatment of primary immune thrombocytopenia and autoimmune hemolytic anemia. The U.S. designation places the same two diseases within the development context cited by the company in its announcement.